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Prevalence and characteristics 
of cutaneous allodynia in probable 
migraine
Seung Min Han1, Kyung Min Kim2, Soo‑Jin Cho3, Kwang Ik Yang4, Daeyoung Kim5, 
Chang‑Ho Yun6 & Min Kyung Chu1*
Cutaneous allodynia (CA) is a pain in response to non‑nociceptive stimulation and a marker of 
central sensitisation. Probable migraine (PM) is a migraine subtype that fulfils all but one criterion 
of migraine. Headache intensity and the disability of individuals with PM are similar or lower than 
individuals with migraine. This study compared CA prevalence and characteristics of PM and migraine 
using a nationally representative sample in Korea. The Allodynia Symptom Checklist‑12 (ASC‑12) was 
used to assess CA (ASC‑12 score ≥ 3). PM and migraine prevalence were 11.6% and 5.0%, respectively. 
CA prevalence did not significantly differ between PM and migraine (14.5% vs. 16.0%, p = 0.701). 
Participants with PM with CA reported a higher monthly headache frequency (3.3 ± 4.3 vs. 1.8 ± 3.6, 
p = 0.044), more severe headache intensity (Visuals Analogue Scale, 6.0 [4.0–7.0] vs. 5.0 [3.0–6.0], 
p = 0.002), and higher impact of headache (Headache Impact Test‑6, 56.3 ± 7.2 vs. 48.3 ± 8.0, p < 0.001) 
than those without CA. Multiple regression analyses revealed that headache frequency and intensity, 
anxiety, and depression were significant factors for CA in participants with PM. In conclusion, CA 
prevalence among participants with PM and migraine were comparable. Anxiety, depression, and 
headache frequency and intensity were significant factors for CA in participants with PM.
Cutaneous allodynia (CA) refers to a pain provoked by stimulation of skin that would ordinarily not produce 
 pain1. The underlying mechanism of CA includes sensitisation of the trigeminal nucleus caudalis, which receives 
afferent input from the meninges and periorbital skin  regions2,3. Central sensitisation is a manifestation of 
increased excitability of neurons in the central nociceptive pathways, and CA is a clinical marker of central 
 sensitisation2–4. It has been reported that a significant proportion of individuals with migraine experience CA 
during episodes of  headache5–7. Individuals with migraine combined with CA were reported to have poorer 
response to acute treatment and a higher rate of progression to chronic migraine (CM) and more severe disability 
compared to individuals with migraine  alone5,8. CA in individuals with migraine was associated with comorbid 
pain conditions, such as irritable bowel syndrome, fibromyalgia (FM), and chronic fatigue  syndrome9. High attack 
frequency, depression, and obesity were reported to be significant factors of CA in these individuals; therefore, 
CA provides clues on the pathophysiology of  migraine7.
The gold standard for the assessment of CA at any particular point in time is quantitative sensory test-
ing (QST)10. Pain thresholds for heat, cold, and pressure stimuli can be assessed by  QST11. Nevertheless, CA 
evaluation using QST is difficult in a clinical setting. The Allodynia 12-item questionnaire (Allodynia Symptom 
Checklist-12, ASC-12) was developed and validated in a large migraine  population5. It showed a close correlation 
with frequency and headache intensity as well as migraine-related  disability12.
Probable migraine (PM) is a subtype of migraine that fulfils all but one criterion of  migraine13. Previous 
studies found that 5–15% of the general population experienced PM during the preceding year, and headache 
intensity and the related disability were comparable or lower among individuals with PM than among those with 
 migraine14–17. A study conducted in the USA reported that the prevalence of CA in PM was slightly lower than 
that in  migraine7. However, there is currently limited information on the associated factors and characteristics 
of CA in individuals with PM in a population-based setting. We hypothesised that, as with migraine, headache 
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frequency, depression, and obesity were significant factors for CA in PM. The present study aimed to investigate 
the prevalence, characteristics, and associated factors of CA in individuals with PM and in those with migraine 
using the ASC-12.
Methods
Survey. We used data derived from the Korean Sleep-Headache Study (KSHS), a nation-wide population-
based cross-sectional survey on headache and sleep. A two-stage stratified clustered sampling method was used 
in the KSHS. Korea is composed of 16 regions (one special city, six metropolitan cities, and nine provinces), 
which were designated as primary sampling units, except Jeju-do, in the first stage. In the second stage, we 
selected representative basic administrative units (cities, counties and districts) from each primary sampling 
unit. Overall, 60 representative basic administrative units were selected from 226 basic administrative units for 
this study. We assigned a target sample size based on age, sex, and occupation to each selected basic adminis-
trative unit as per data from the 2016 population and housing census by the National Statistical  Office18. We 
targeted 2500 individuals aged ≥ 19 years. The estimated sampling error was ± 1.9%. The survey was conducted 
via door-to-door visits and face-to-face interviews using questionnaires by trained interviewers. All interview-
ers were employees of Gallup Korea and were not medical personnel. The KSHS survey was conducted between 
October 2018 and November 2018.
PM and migraine diagnosis. PM was diagnosed according to the third edition of the International Clas-
sification of Headache Disorders (ICHD-3; code 1.5)13. If the characteristics and accompanying symptoms of a 
participant’s headache fulfilled all but one of the A–D criteria of migraine without aura, a diagnosis of PM was 
established.
Migraine was diagnosed based on the diagnostic criteria for migraine without aura according to code 1.1 of 
ICHD-313. If the characteristics and accompanying symptoms of a participant’s headache fulfilled the A–D criteria 
of migraine without aura, a diagnosis of migraine was established. We previously evaluated the diagnostic ability 
of our questionnaire for migraine by comparing the diagnosis using the questionnaire and diagnosis made by 
neurologists with an additional telephone  interview16. We did not separately analyse participants according to 
the presence of aura; therefore, migraine included both migraine with aura (ICHD-3 code 1.2) and migraine 
without aura (ICHD-3 code 1.1) in the present study. Accordingly, PM included both PM with aura (ICHD-3 
code 1.5.2) and PM without aura (ICHD-3 code 1.5.1).
Assessment of CA. We investigated CA using the 12-item Allodynia Symptom Checklist (ASC-12). The 
ASC-12 measures interictal CA over the previous month using 12 questions on the thermal, mechanical static, 
and mechanical dynamic symptoms of  CA5. Participants were asked to rate 12 questions using any of the follow-
ing responses: ‘does not apply to me’; ‘never’; ‘rarely’; ‘less than half the time’; and ‘half the time or more’. The first 
three responses were scored as 0, while ‘less than half of the time’ was scored as 1, and ‘half the time or more’ was 
scored as 2. The sum of the scores in the 12 items of ASC-12 was the ASC-12 score. If the ASC-12 score was ≥ 3, 
the participant was identified as having CA. The ASC-12 scores were further sub classified into mild (score 3–5), 
moderate (score 6–8), and severe (score ≥ 9) CA,  respectively6.
Impact and disability of headache. The impact of headache was assessed using the Headache Impact 
Test-6 (HIT-6)20. We used the Korean version of HIT-6, which was previously validated in the Korean  language21. 
We used the migraine disability assessment (MIDAS) questionnaire to assess headache-related  disability22. The 
MIDAS questionnaire is composed of five questions on the loss of or decrease in productive days due to head-
ache during the previous 3 months. The MIDAS questionnaire was previously validated in the Korean language 
with good sensitivity and  specificity23.
Assessment of depression and anxiety. Depression was assessed by the Patient Health Questionnaire-9 
(PHQ-9)24. Participants with PHQ-9 scores of 10 or more were defined as having depression. The Korean version 
of the PHQ-9 has been evaluated showing a sensitivity of 81.1% and a specificity of 89.9%25.
We used the Generalized Anxiety Disorder-7 (GAD-7) questionnaire to evaluate  anxiety26. A participant 
giving a positive response to seven or more items was classified as having anxiety. The Korean version of GAD-7 
was validated with a sensitivity of 78.1% and a specificity of 74.6%27.
Ethical approval. This study was approved by the Institutional Review Board of Severance Hospital, Yonsei 
University (approval No. 2019–1721-001). Written informed consent was obtained from all participants Prior 
to obtaining written informed consent, all participants were given an explanation on the objective of the study 
and the data to be collected by interviewers. All procedures involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee as well as the tenets of the 1964 
Declaration of Helsinki and its later amendments, or comparable ethical standards.
Statistical analyses. The 1-year prevalence of migraine was calculated as the number of cases per 100 
persons. Binary and ordinal scales are represented as numbers and percentages. Interval scales are represented 
as mean and standard deviation or median and interquartile range (IQR) when appropriate. Normality of the 
ratio of variables was tested with the Kolmogorov–Smirnov test. After normality was confirmed, independent 
two-tailed t-tests or one-way analyses of variance were used to compare the variables between the groups when 
appropriate. For non-normally distributed variables, a two-tailed Mann–Whitney U test or Kruskal–Wallis test 
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was used. To compare interval variables between the groups, we used a Mann–Whitney U test or Kruskal–Wallis 
test and summarised the data as median (IQR). A two-tailed chi-squared test was used to compare the binary 
and ordinal scales. No statistical power calculation was conducted before commencing the study, and the sample 
size used was based on the available data. Post hoc comparisons were performed using a Bonferroni’s correction 
(p = 0.05/3, 0.017) to adjust for multiple testing among the three groups.
Since the prevalence of PM and migraine varied significantly according to sex and age, we compared clinical 
characteristics of PM and migraine according to the presence of CA with age and sex  adjustment16,28. Logistic 
regression analyses after age (year, continuous) and sex adjustment were used to compare categorical variables 
according to the presence of CA in PM and migraine. Linear regression analyses with age and sex adjustment 
were used to compare numerical variables.
We evaluated the odds ratios with 95% confidence interval to determine the factors contributing to CA 
using univariable and multivariable logistic regression analyses. In individuals with migraine and PM, factors 
that demonstrated significant differences between those with CA and those without CA were included in the 
univariable analyses. For multivariable analyses, sociodemographic variables (age, sex, and educational level), 
headache-related parameters (the intensity and frequency of headache) and psychiatric conditions (anxiety 
[GAD-7] and depression [PHQ-9]) were included to examine the association of CA with migraine and PM.
SPSS v24.0 (IBM, Armonk, NY, USA) was used to perform the statistical analyses. Statistical significance 
was set at two-tailed p < 0.050. The current analysis is the primary analysis for prevalence of CA in PM using 
KSHS data. Imputation techniques were not used to minimise non-response effects. The approach used in this 
study will produce slightly larger standard errors in finite samples when compared with imputation  techniques29.
Results
Survey. Overall, 2501 participants completed the survey. The distribution of sex, age, and educational level 
among our participants did not significantly differ from that of the total population of Korea (Table 1). Therefore, 
there was no need to use extracted sampling weights in the statistical analyses.
Of the 2501 participants, 1186 responded positively to the question ‘Did you have headache during the 
previous one year?’. Of the 1186 respondents, 289 (11.6%) and 125 (5.0%) participants had PM and migraine, 
respectively (Fig. 1). Of the 289 participants with PM, 193 (66.8%) missed the typical duration (criterion B), 94 
(32.5%) missed the typical headache characteristics (criterion C), and two (0.7%) missed the typical accompany-
ing symptoms (criterion D) of migraine without aura.
There were no missing data except for PHQ-9, weight, and height. Among all participants, PHQ-9, height 
and weight data were missing for 3, 7, and 21 participants, respectively. Among participants with PM, the height 
data was missing for one participant. Among participants with migraine, weight and height data were missing 
for two and one participant, respectively. No PHQ-9 data was missing for any participants with migraine or PM.
CA in individuals with PM and migraine. The responses to the ASC-12 among participants with PM 
and migraine are summarised in Table 2. Among participants with PM, ‘exposure to cold’ was the most com-
mon response with less than half of the time or more frequency, and ‘resting your face or head on a pillow’ was 
the next most frequent response. The items ‘wearing a necklace’ and ‘wearing earrings’ demonstrated the least 
frequencies. Of 289 participants with PM, 12 (4.1%), 15 (5.2%), and 15 (5.2%) participants were identified with 
mild, moderate, and severe CA, respectively. The prevalence of CA among participants with PM missing the 
Table 1.  Sociodemographic distribution of survey participants and participants identified as having probable 
migraine and migraine in the 2018 survey as proportions of the overall population. CI: confidence interval.
Survey participants, 
N (%) Total population N (%) p-value
Probable migraine, % 
(95% CI) Migraine, % (95% CI)
Sex
Male 1242 (49.6) 21,024,909 (48.9) 0.977 9.8 (8.2–11.5) 4.0 (2.9–5.1)
Female 1259 (50.4) 21,544,156 (50.1) 13.3 (11.4–15.1) 6.0 (4.7–7.3)
Age, years
19–29 434 (17.3) 7,624,184 (17.8) 1.000 11.1 (8.1–14.0) 4.3 (2.4–6.3)
30–39 425 (17.0) 7,446,677 (17.3) 8.9 (6.2–11.7) 7.8 (5.2–10.3)
40–49 498 (19.9) 8,408,883 (19.6) 13.7 (10.6–16.7) 4.8 (2.9–6.7)
50–59 498 (19.9) 8,515,725 (19.8) 12.0 (9.2–14.9) 4.6 (2.8–6.5)
60–69 345 (13.8) 5,854,493 (13.6) 11.6 (8.2–15.0) 4.4 (2.2–6.5)
 > 70 301 (12.0) 5,082,994 (11.8) 11.6 (7.9–15.3) 3.7 (1.6–5.8)
Educational level
Middle school or less 393 (15.7) 5,194,888 (12.1) 0.607 10.9 (7.8–14.0) 4.1 (2.1–6.0)
High school 1063 (42.5) 17,130,249 (39.9) 12.2 (10.3–14.2) 4.9 (3.6–6.2)
College of more 1045 (41.8) 20,607,819 (48.0) 11.1 (9.2–13.0) 5.4 (4.1–6.8)
Total 2501 (100.0) 42,932,956 (100.0) 11.6 (10.3–12.8) 5.0 (4.1–5.9)
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typical duration was significantly higher than that among participants with PM missing the typical characteris-
tics of headache (19.2% vs. 5.3%, respectively, p = 0.002).
Among in participants with migraine, CA was most frequently reported with ‘exposure to cold’ (less than half 
of the time or half of the time or more), followed by ‘combing hair’ and ‘resting your face or head on a pillow’. The 
items ‘wearing a necklace’ and ‘wearing earrings’ demonstrated the least frequent positive responses. Finally, 11 
Figure 1. .  Flow chart depicting the inclusion of participants in the study. CA cutaneous allodynia, PM 
probable migraine.
Table 2.  Responses to the Allodynia Symptom Checklist-12 by individuals with probable migraine and 
migraine. ASC-12: Allodynia Symptom Checklist-12, N/A: not applicable.
Question: 
How often do 
you experience 
increased 









engage each of 
the following?
Probable migraine, N = 289 Migraine, N = 125
Never, N (%) Rarely, N (%)
Less than half, 
N (%)
Half the time 
or more, N 
(%) N/A, N (%) Never, N (%) Rarely, N (%)
Less than half, 
N (%)
Half the time 
or more, N 
(%) N/A, N (%)
Combing hair 176 (60.9) 75 (26.0) 16 (5.5) 12 (4.2) 10 (3.5) 75 (58.4) 35 (28.0) 6 (4.8) 8 (6.4) 3 (2.4)
Pulling your 
hair back 160 (55.4) 81 (28.0) 16 (5.5) 8 (2.8) 24 (8.3) 67 (53.6) 33 (26.4) 6 (4.8) 6 (4.8) 13 (10.4)
Shaving your 
face 116 (40.1) 19 (6.6) 12 (4.2) 7 (2.4) 135 (46.7) 48 (38.4) 12 (9.6) 4 (3.2) 3 (2.4) 58 (10.4)
Wearing 
eyeglasses 103 (35.6) 28 (9.7) 12 (4.2) 7 (7.4) 139 (48.1) 34 (27.2) 16 (12.8) 4 (3.2) 0 (0.0) 71 (56.8)
Wearing con-
tact lens 86 (29.8) 14 (4.8) 11 (3.8) 2 (0.7) 176 (60.9) 32 (25.6) 6 (4.8) 2 (1.6) 0 (0.0) 85 (68.0)
Wearing ear-
rings 144 (49.8) 29 (10.0) 9 (3.1) 0 (0.0) 107 (37.0) 59 (47.2) 10 (8.0) 1 (0.8) 0 (0.0) 55 (44.0)
Wearing a 
necklace 152 (52.6) 23 (8.0) 12 (4.2) 2 (0.7) 100 (34.6) 65 (52.0) 10 (8.0) 1 (0.8) 0 (0.0) 49 (39.2)
Wearing tight 
clothing 150 (51.9) 60 (20.8) 17 (5.9) 9 (3.1) 53 (18.3) 64 (51.2) 17 (13.6) 8 (6.4) 3 (2.4) 33 (26.4)
Taking a 
shower 184 (63.7) 68 (23.5) 21 (7.3) 9 (3.1) 7 (2.4) 79 (63.2) 35 (28.0) 7 (5.6) 0 (0.0) 4 (3.2)
Resting your 
face or head on 
a pillow
169 (58.5) 83 (28.7) 26 (9.0) 7 (2.4) 4 (1.4) 59 (47.2) 48 (38.4) 6 (4.8) 8 (6.4) 4 (3.2)
Exposure to 
heat 162 (56.1) 96 (33.2) 25 (8.7) 2 (0.7) 4 (1.4) 64 (51.2) 46 (36.8) 6 (4.8) 4 (3.2) 5 (4.0)
Exposure to 
cold 135 (46.7) 113 (39.1) 29 (10.0) 8 (2.8) 4 (1.4) 56 (44.8) 46 (36.8) 12 (9.6) 6 (4.8) 5 (4.0)
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(8.8%), seven (5.6%), and two (1.6%) participants with migraine were identified with mild, moderate, and severe 
CA, respectively. There was no significant difference in the prevalence of CA among participants with PM accord-
ing to the headache frequency (< 1 episode per month, 1–14 episodes per month, and ≥ 15 episode per month 
p = 0.725, Fig. 2A). Conversely, there was significant differences in the prevalence of CA among participants with 
migraine according to headache frequency (p = 0.017). However, post hoc analyses revealed no significant dif-
ference among the three groups (Fig. 2B). The overall prevalence of CA was not significantly different between 
participants with PM and those with migraine (14.5% vs. 16.0%, respectively, p = 0.701).
Clinical characteristics of PM and migraine according to the presence of CA. Headache fre-
quency per month, headache intensity (Visual Analogue Scale), impact of headache (HIT-6), and disability 
(MIDAS) were significantly higher among participants with PM and migraine combined with CA than among 
those without CA. Anxiety and depression were more prevalent among both participants with PM and migraine 
with CA than among those without CA. Considering participants with migraine, anxiety was more severe among 
participants with migraine with CA than among those without CA. Nevertheless, the severity of depression was 
not significantly different according to the presence of CA. Photophobia and phonophobia were more prevalent 
among participants with PM combined with CA; however, there was no significant difference in photophobia 
and phonophobia according to the presence of CA among participants with migraine (Table 3).
Factors associated with CA in PM and migraine. For participants with PM, univariable analyses 
revealed that moderate and severe headache intensity, anxiety, and depression were significantly associated with 
CA. In multivariable analyses, moderate and severe headache intensity, anxiety, and depression were signifi-
cantly associated with CA (Table 4).
Univariable analyses in participants with migraine indicated that ≥ 15 headaches per month, moderate and 
severe headache intensity, anxiety, and depression were significantly associated with CA. Multivariable analyses 
revealed that only anxiety was significantly associated with CA (Table 4).
Discussion
The primary findings of the present study were the following: (1) approximately one-sixth of participants with 
PM and migraine experienced CA, and the prevalence of CA was not significantly different between those with 
PM and those with migraine; (2) participants with PM and migraine with CA experienced more severe symptoms 
and a greater impact of headache and disability than those without CA; and (3) headache intensity, anxiety, and 
depression were significant factors of CA in participants with PM. In participants with migraine, anxiety was a 
significant factor of CA.
Allodynia is classified as mechanical dynamic, mechanical static, and thermal allodynia. These types differ 
in terms of the transmission nerve fibres and  nociceptors30,31. Each item of the ASC-12 comprised three types of 
CA. ‘Exposure to cold’ and ‘resting your face or head on pillow’ corresponded to thermal allodynia, and ‘combing 
hair’ and ‘pulling your hair back’ items corresponded to mechanical dynamic  allodynia5. High positive response 
rate to items of thermal and mechanical dynamic allodynia among individuals with migraine was previously 
reported in a Brazilian  study32. The present study found that ‘exposure to cold’ and ‘resting your face or head 
on pillow’ were the most frequently reported positive items among both individuals with PM and migraine. 
‘Combing hair’ and ‘pulling your hair back’ was the next most frequent positive response. The present study is 
the first to identify a high for positive response rate for items corresponding to thermal and mechanical dynamic 
allodynia in individuals with PM, which is comparable to that in individuals with migraines.
We included participants with PM and migraine who had at least one headache attack during the preceding 
year. Nevertheless, some individuals with PM and migraine had a headache frequency of < 1 attack per  year33. 
These individuals may not have been classified as having migraine and PM in our study. Participants with 
migraine and PM with a headache frequency of < 1 attack per year may have different prevalence and clinical 
Figure 2..  Prevalence of cutaneous allodynia in participants with probable migraine (A) and migraine (B) 
according to headache frequency per month.
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Table 3.  Clinical characteristics of probable migraine and migraine according to the presence of cutaneous 
allodynia. PM: probable migraine, CA: cutaneous allodynia, MIDAS: migraine disability assessment, HIT-6: 
Headache Impact Test-6, PHQ-9: Patient Health Questionnaire-9, GAD-7: Generalized Anxiety Disorder-7. 
*Median and interquartile range. † Compared using linear regression analyses with age and sex (year, 
continuous) adjustment.
PM Migraine
PM with CA, N = 42 PM without CA, N = 247 p-value† Migraine with CA, N = 20 Migraine without CA, N = 105 p-value†
Headache frequency per month 3.3 ± 4.3 1.8 ± 3.6 0.017 5.6 ± 8.4 2.1 ± 3.5 0.857
Headache intensity (Visual Analogue 
Scale) 6.0 (4.0–7.0)* 5.0 (3.0–6.0)* 0.002 7.0 (6.0–7.0)* 6.0 (5.0–7.0)* 0.033
Attack duration (hours) 2.2 ± 0.9 1.5 ± 1.1  < 0.001 9.1 ± 7.8 7.6 ± 6.6
Unilateral pain 19 (45.2) 145 (58.6) 0.097 14 (70.0) 73 (69.5) 0.937
Aggravation by movement 27 (64.3) 86 (34.8)  < 0.001 11 (55.0) 48 (45.7) 0.501
Pulsating quality 31 (73.8) 197 (86.4) 0.337 15 (75.0) 87 (82.8) 0.547
Nausea 38 (90.5) 230 (93.1) 0.467 19 (95.0) 93 (88.6) 0.448
Vomiting 19 (45.2) 117 (47.4) 0.828 12 (60.0) 44 (41.9) 0.168
Photophobia 25 (59.5) 67 (27.1) 0.017 8 (40.0) 37 (35.2) 0.755
Phonophobia 29 (69.0) 112 (45.3) 0.007 11 (55.0) 55 (52.4) 0.917
Osmophobia 21 (50.0) 95 (38.5) 0.202 7 (35.0) 41 (39.0) 0.624
Depression (PHQ-9 score) ≥ 10 22 (52.4) 40 (16.2)  < 0.001 7 (35.0) 17 (16.2) 0.047
PHQ-9 score 11.1 ± 5.5 7.8 ± 3.5 0.150 8.6 ± 4.9 7.9 ± 3.7 0.520
Anxiety (GAD-7 score) ≥ 7 14 (33.3) 13 (5.3)  < 0.001 9 (45.0) 11 (10.5)  < 0.001
GAD-7 score 4.7 ± 5.0 2.0 ± 2.6 0.312 6.6 ± 5.4 2.2 ± 2.8  < 0.001
HIT-6 score 56.3 ± 7.2 48.3 ± 8.0  < 0.001 61.5 ± 9.2 51.4 ± 7.9  < 0.001
MIDAS score 1.0 (0.0–10.0)* 0.0 (0.0–1.0)* 0.029 5.0 (2.0–13.8)* 0.0 (0.0–2.0)*  < 0.001
Body mass index 23.1 ± 2.4 23.0 ± 2.6 0.625 22.7 ± 2.5 22.8 ± 2.5 0.116
Table 4.  Factors associated with cutaneous allodynia in individuals with probable migraine in univariable and 
multivariable analyses. OR: odds ratio, CI, confidence interval, GAD-7: Generalized Anxiety Disorder-7, PHQ-
9: Patient Health Questionnaire-9. REF: Reference. *No participant with migraine aged > 70 had cutaneous 
allodynia. † No participant with migraine had an educational level of middle school or less.
Probable migraine Migraine
Univariable OR, 95% CI
Multivariable OR, 95% 
CI Univariable OR, 95% CI Multivariable OR, 95% CI
Sex (Female) 1.4 (0.7–2.7) 1.4 (0.6–3.2) 1.3 (0.5–3.5) 1.0 (0.3–3.8)
Age (year)
20–29 REF REF REF REF
30–39 1.1 (0.4–3.5) 1.5 (0.4–5.6) 1.4 (0.3–6.4) 1.1 (0.2–5.9)
40–49 0.6 (0.2–1.7) 0.8 (0.2–2.9) 1.4 (0.3–6.8) 0.5 (0.1–3.3)
50–59 0.9 (0.3–2.5) 1.2 (0.3–2.9) 0.5 (0.07–3.4) 0.2 (0.2–1.7)
60–69 0.6 (0.2–2.0) 0.4 (0.1–2.3) 1.3 (0.3–7.8) 0.2 (0.1–4.9)
 > 70 1.3 (0.4–3.8) 1.4 (0.3–8.2) 0.0 (0.0–0.0)* 0.0 (0.0–0.0)*
Educational level
High school REF REF REF REF
Middle school or less 1.6 (0.6–4.2) 1.6 (0.4–6.3) 0.0 (0.0–0.0)† 0.0 (0.0–0.0)†
College or more 1.3 (0.6–2.7) 0.9 (0.3–2.4) 0.9 (0.3–2.4) 0.4 (0.1–1.5)
Headache frequency per month
 < 1 REF REF REF REF
1–14 1.3 (0.7–2.5) 0.6 (0.2–1.3) 2.5 (0.9–7.3) 1.0 (0.3–3.8)
 ≥ 15 1.6 (0.2–15.4) 1.1 (0.1–11.9) 9.8 (1.6–59.9) 2.6 (0.4–18.6)
Headache intensity
Mild REF REF REF REF
Moderate 2.7 (1.3–5.8) 2.4 (1.1–5.4) 2.5 (1.6–4.0) 0.9 (0.2–4.6)
Severe 5.7 (1.9–16.8) 4.0 (1.1–13.9) 8.5 (4.4–16.1) 2.6 (0.4–18.6)
Anxiety (GAD-7 score ≥ 7) 9.0 (3.8–21.1) 5.2 (1.7–16.3) 11.3 (2.5–52.4) 11.6 (2.0–67.3)
Depression (PHQ-9 
score ≥ 10) 5.7 (2.8–11.4) 3.3 (1.5–7.6) 2.8 (1.0–8.0) 1.1 (0.2–5.3)
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features of CA compared to those with a frequency of ≥ 1 attack per year. Although most individuals with 
migraine had a headache frequency of ≥ 1 attack per year, the findings in the present study were only applicable 
to PM and migraine, with headache a headache frequency of ≥ 1 attack per  year33.
Previous studies have shown that a significant proportion of individuals with migraine had CA. The Ameri-
can Migraine Prevalence and Prevention (AMPP) study, a large population-based study in the USA, reported 
that 62% of individuals with migraine had  CA7. Migraine in America Symptoms and Treatment (MAST) study, 
another American large population-based study, reported that the prevalence of CA in individuals with migraine 
was 40%6. A Dutch cohort study revealed that CA was present in 70% of individuals with  migraine8. The present 
study found that 16.0% of individuals with migraine had CA. These values were lower than those reported in 
previous studies in Western countries but results were comparable to those reported in a Korean clinic-based 
study, which found that 14.5% of individuals with migraine had  CA19. One possible explanation for the lower 
prevalence of CA in the present study is the difference in migraine symptoms in Asian countries. Symptoms are 
milder in Asian countries than in Western countries. Moderate headache intensity has been reported in 30–65% 
of individuals with migraines in Asian  countries34,35. In Western countries, 80–85% of individuals with migraine 
reported severe headache  intensity36,37. Photophobia has been reported in 40–65% of individuals with migraine 
in Asian countries and 75–85% of individuals with migraine in Western  countries34,37–39. Headache intensity and 
photophobia were significant predictors of CA in individuals with  migraine6. Another possible explanation is the 
difference in body mass index (BMI), which is lower in Asian populations than in Western  populations40. High 
BMI was reported to be a significant factor for CA in the AMPP  study5 with obese (BMI, 30–40 kg/m2) and mor-
bidly obese (BMI, ≥ 40 kg/m2) individuals having a higher risk of CA. In the present study, only four participants 
with PM and two participants with migraine were obese. Furthermore, none of the participants with migraine 
and PM qualified for morbid obesity. The 1-year based diagnostic strategies for PM and migraine in our study 
could be another possible reason for the discrepancy in the prevalence of CA between our study and previous 
reports. The Dutch and Brazilian studies enrolled individuals with migraine regardless of headache frequency 
and reported a high prevalence of  CA32,41. The AMPP study recruited individuals who had at least one severe 
headache in the previous year and reported a comparable prevalence of  CA5. The MAST study, which included 
individuals with migraine with monthly headache frequency, reported a slightly lower prevalence of CA than that 
in other studies but higher than CA prevalence found in our  study42. The present study identified participants 
with PM and migraine with a headache frequency of ≥ 1 attack per year and reported a lower prevalence of CA 
compared to previous studies. Ethnic differences could be another possible explanation. It has been reported that 
pain sensitivity varies among ethnic  groups43. Further studies in different migraine populations are required for 
a better understanding of the prevalence and contributing factors of CA.
In the present study, headache intensity, disability, and impact of headache were higher among participants 
with PM and migraine combined with CA than among those without CA. The close associations of CA with 
symptom severity and chronicity have been previously reported in  migraine5,7. The present study provides evi-
dence that such an association is also present between CA and PM.
In the present study, anxiety and depression were identified as significant factors for CA in individuals with 
PM. A significant association of anxiety and depression with CA has been reported previously. Kao et al. reported 
that anxiety was a significant factor of CA using multivariable regression analyses. Furthermore, comorbid anxi-
ety and depression were also associated with CA  severity44. Louter et al. reported that CA was associated with 
higher prevalence of depression among individuals with  migraine41. CA, anxiety, and depression were significant 
risk factors of CM transformation from episodic migraine (EM)8,45. CM has a higher prevalence in the presence 
of anxiety, depression, and CA than  EM7. Therefore, our findings corroborate existing evidence that supports 
the significant association of anxiety and depression with CA, suggesting shared pathophysiological mechanisms 
with anxiety and depression. Biogenic amines may be involved in a possible common  mechanism46. Allodynia is 
a characteristic of FM, which is a chronic condition of widespread  pain47. In an animal model of FM, decreased 
tactile threshold correlated with depressive  behaviors48. The animal model demonstrated a decreased level of 
biogenic amines including dopamine, 5-hydroxytryptoptamine, and norepinephrine in the spinal cord, thalamus, 
and prefrontal  cortex48.
The prevalence of migraine in the present study was lower than that in previous Western studies. The prev-
alence of migraine in Asian countries is 3–10%, which is lower than that in Western countries reported as 
11–18%28. Therefore, migraine prevalence in the present study was similar to that in previous Asian studies. The 
reported prevalence of PM ranges widely (USA, 4.5%; Singapore, 6.2%; France, 10.0%; Korea. 11.5%; England: 
14.6%)14,15,17,49; therefore, the prevalence of PM in the present study was broadly similar to that reported in 
previous studies.
The present study has several limitations. Firstly, we used the ASC-12 in the evaluation of CA. The gold 
standard for the assessment of CA is QST; however, this requires specialised equipment and is difficult to con-
duct in clinical practice and epidemiological studies. The ASC-12 was previously validated in comparison with 
 QST8. It was originally written in English and has been translated into Portuguese, Spanish and  Korean32,50,51. 
The Korean translation was constructed through forward and backward translation by a translator and reli-
ability was assessed by calculating internal consistency of items. Portuguese and Spanish translations of the 
ASC-12 were not validated in comparison with QST, but studies using these two translations revealed similar 
prevalence of CA among individuals with migraine compared to studies using the English version ASC-1232,50. 
Using a Korean translation of the ASC-12, which was not fully validated, could be a limitation of our  study52. 
Secondly, we did not evaluate cooperation rate in our survey. We conducted a headache survey in 2009 using the 
same sampling method, except for target sample size, and involving the same social research company, Gallup 
 Korea16. Cooperation in the 2009 survey was 38.6% and we assume that the cooperation rate in this study may 
be comparable. The distribution of age, sex and educational level in this study was similar to that of the total 
population of Korea in the 2009 survey and KSHS. Furthermore, the one-year prevalence of migraine in the 2009 
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survey (6.1%) and the present study (5.0%) was similar to the reported prevalence in Asian  countries53. Finally, 
we did not evaluate the use of medication among participants. Some types of medication for migraine prevention, 
such as serotonin-norepinephrine reuptake inhibitors and anticonvulsants, may relieve  CA54–56. Further studies 
including medication use are required to provide accurate information of CA in patients with migraine and PM.
The present study has several strengths. Firstly, we used a two-stage clustered random sampling method pro-
portional to the distribution of the total population of Korea. Furthermore, the estimated sampling error was low. 
This approach allowed us to successfully assess CA in individuals with migraine and PM in a population-based 
setting. Secondly, in the present study, we analysed the responses of 12 items in addition to the total ASC-12 
score. We found that ‘exposure to cold’, ‘resting your face or head on a pillow’, and ‘combing hair’ were the most 
frequent responses given by participants with migraine and PM. Thirdly, our study used questionnaires that 
were specialized validated in the Korean language for assessing migraine, anxiety and depression. This process 
allowed us to accurately evaluate migraine, PM, anxiety and depression.
In conclusion, approximately one-sixth of individuals with PM experienced CA in a general-population-
based sample in Korea. The prevalence of CA was not significantly different between participants with PM and 
those with migraine. Anxiety, depression, and high frequency of headaches were significant factors of CA among 
participants with PM.
Data availability
The data used in this study are available from the corresponding author on reasonable request.
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